Follow The Filings

REPL Replimune Group

Replimune Group earnings company data as of 4:47 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2027 Q1 14 Aug EPS — -0.72 —
Rev — — —

Insider trades

Open-market buys and sales by REPL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All REPL insider trades
  • None no insider bought on the open market
  • $33K sold by 1 insider outside a trading plan
  • $274K sold by 2 insiders under 10b5-1 plans
  1. Christopher Sarchi Chief Commercial Officer
    Planned sale
    $111K 12,000 shares at $9.24 6.2% of stake
    Traded Jun 1 Filed Jun 3
  2. Christopher Sarchi Chief Commercial Officer
    Planned sale
    $52K 6,500 shares at $8.01 4.1% of stake
    Traded Apr 2 Filed Apr 6
  3. Kapil Dhingra Director
    Sale
    $33K 3,169 shares at $10.40 100% of stake
    Traded Dec 9, 2025 Filed Dec 11, 2025
  4. Sushil Patel CEO
    Planned sale
    $111K 10,000 shares at $11.13 2.9% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025

Also filed in the last 12 months, not counted as buying or selling: 13 sales to cover taxes, 11 stock grants, 2 gifts, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.03,5.07,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13D/A —
8-K/A 8.01,9.01
SCHEDULE 13G —
424B5
8-K 8.01,9.01
SCHEDULE 13G —
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 8.01,9.01
8-K 7.01,9.01
DEF 14A FORM -DEF 14A
DEFA14A
8-K 2.02,9.01
10-K
8-K 7.01,9.01
8-K 7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 7.01,8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.